Efficacy evaluation of targeted therapy in patient with gastrointestinal stromal tumor
Abstract
An evaluation of efficacy of Gleevec in gastrointestinal stromal tumor is under discussion. Standard RECIST criteria underestimate the tumor response in contrast with highly sensitive PET evaluation. Proposed criteria modifications offer CT response evaluation. We demonstrated a difference between response criteria presenting a clinical case.
About the Authors
A. A. Meshcheryakov
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
N. T. Tsymzhitova
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
D. A. Filonenko
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
B. M. Medvedeva
FGBU N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
References
1. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981, v. 47, p. 207-214.
2. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J. Natl. Cancer Inst. 2000, v. 92, p. 205-216.
3. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009, v. 45, p. 228-247.
4. Van den Abbeele A., Badawi R., Clich J. et al. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. 2002, 21a, 403a (abstr. 1610).
5. Choi H., Charnsangavej C., de Castro Faria S. et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am. J. of Roentgenol. 2004, v. 183, p. 1619-1628.
6. Choi H., Charnsangavej C., Faria S.C. et al. Correlation of computer tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 2007, v. 25 (13), p. 1753-1759.
7. Le Cesne A., Van Glabbeke M., Verweij J. et al. Absence of progression as assessed by Response Evaluation Criteria in Solid Tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J. Clin. Oncol. 2009, doi: 10.1200/ JCO.2008.21.3330.
Review
For citations:
Meshcheryakov A.A., Tsymzhitova N.T., Filonenko D.A., Medvedeva B.M. Efficacy evaluation of targeted therapy in patient with gastrointestinal stromal tumor. Bone and soft tissue sarcomas, tumors of the skin. 2013;(2):38-42. (In Russ.)
Views:
54
Email this article 
